ABSTRACT
Integrative methods, like colocalization and transcriptome-wide association studies (TWAS), identify transcriptomic mechanisms at only a small fraction of trait-associated genetic loci from genome-wide association studies (GWAS). Here, we show that a reliance on reference functional genomics panels of only total gene expression greatly contributes to this reduced discovery. This is particularly relevant for neuropsychiatric traits, as the brain expresses extensive, complex, and unique alternative splicing patterns giving rise to multiple genetically-regulated transcript-isoforms per gene.
We introduce isoTWAS, a scalable, multivariate framework to integrate genetics, isoform-level expression, and phenotypic associations in a step-wise testing framework. Multivariate predictive models were trained using isoform-level expression across tissues from the Genotype-Tissue Expression Project and in the developing and adult human brain from PsychENCODE. Across five neuropsychiatric traits, isoTWAS dramatically increased discovery of trait associations within GWAS loci, capturing 92 unique loci compared with 27 using gene-level TWAS. These power gains reflected a ∼2-fold increase in the number of testable genes, an ∼15-35% increase in total gene expression prediction accuracy, and the ability to jointly capture expression and splicing mechanisms. Results from extensive simulations showed no increase in false discovery rate and reinforce isoTWAS’s advantages in prediction and trait mapping power over TWAS, especially when genetic effects on expression vary across isoforms of the same gene. We illustrate multiple biologically-relevant isoTWAS-identified trait associations undetectable by gene-level methods, including isoforms of AKT3, GIGFY2, and KMT5A with schizophrenia risk.
The isoTWAS framework addresses an unmet need to consider the transcriptome on the transcript-isoform level to maximize discovery of trait associations, especially for brain-relevant traits.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
BP was partially supported by NIH awards R01 HG009120, R01 MH115676, R01 CA251555, R01 AI153827, R01 HG006399, R01 CA244670, and U01 HG011715. MJG was supported by SFARI Bridge to Independence Award, NIMH R01-MH121521, NIMH R01-MH123922, and NICHD-P50-HD103557.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study uses only openly available human data originally located at the following locations. GTEx genetic, transcriptomic, and covariate data were obtained through dbGAP approval at accession number phs000424.v8.p2. Linkage disequilibrium reference data from the 1000 Genomes Project were obtained at this link: https://www.internationalgenome.org/data-portal/sample. GWAS summary statistics were obtained at the following links: ADHD (https://www.med.unc.edu/pgc/download-results/), ALZ (https://ctg.cncr.nl/software/summary_statistics/), ASD (https://www.med.unc.edu/pgc/download-results/), BD (https://www.med.unc.edu/pgc/download-results/), and SCZ (https://www.med.unc.edu/pgc/download-results/). The RNA-seq and genotype dataset from Walker et al is available at dbGAP with accession number phs001900. The subset of data from the CommonMind Consortium from the PsychENCODE Consortium is available at doi.org/10.7303/syn12080241.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
GTEx genetic, transcriptomic, and covariate data were obtained through dbGAP approval at accession number phs000424.v8.p2. Linkage disequilibrium reference data from the 1000 Genomes Project were obtained at this link: https://www.internationalgenome.org/data-portal/sample. GWAS summary statistics were obtained at the following links: ADHD (https://www.med.unc.edu/pgc/download-results/), ALZ (https://ctg.cncr.nl/software/summary_statistics/), ASD (https://www.med.unc.edu/pgc/download-results/), BD (https://www.med.unc.edu/pgc/download-results/), and SCZ (https://www.med.unc.edu/pgc/download-results/). The RNA-seq and genotype dataset from Walker et al is available at dbGAP with accession number phs001900. The subset of data from the CommonMind Consortium from the PsychENCODE Consortium is available at doi.org/10.7303/syn12080241. isoTWAS models for GTEx and PsychENCODE are available at https://zenodo.org/record/679594769.
https://www.internationalgenome.org/data-portal/sample
